Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Leah Dickerson

Psychiatry Jeffersonville, IN Medical Doctor

NPI 1235291238 CMS profile 101655

460 Spring St, Jeffersonville, IN 47130

Open in the dashboard

General payments

$9,376

675 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Leah Dickerson of Jeffersonville, IN is reported in the CMS Open Payments database as having received $9,376 across 675 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,361 86
2024 General $1,102 67
2023 General $1,217 80
2022 General $1,311 98
2021 General $1,997 145
2020 General $1,424 119
2019 General $966 80

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Leah Dickerson
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Leah Dickerson were reported at $1,361. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Leah Dickerson Psychiatry median Middle half National median
2019 $966 $184 $59–$605 $163
2020 $1,424 $119 $36–$372 $114
2021 $1,997 $143 $43–$576 $132
2022 $1,311 $153 $50–$590 $149
2023 $1,217 $170 $56–$651 $160
2024 $1,102 $179 $57–$673 $164
2025 $1,361 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. ITI, Inc. $1,135 72 payments
  2. Otsuka America Pharmaceutical, Inc. $1,062 71 payments
  3. Neurocrine Biosciences, Inc. $1,046 79 payments
  4. Vanda Pharmaceuticals Inc. $921 49 payments
  5. AbbVie, Inc. $815 92 payments
  6. Teva Pharmaceuticals USA, Inc. $710 50 payments
  7. Lundbeck LLC $677 47 payments
  8. Janssen Pharmaceuticals, Inc $631 40 payments
  9. Alkermes, Inc. $581 31 payments
  10. Sunovion Pharmaceuticals Inc. $479 30 payments
  11. Other $1,319 114 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,201 671 payments
  2. Education $176 4 payments
Products named General payments · program years 2019–2025
  1. FANAPT $921 49 payments
  2. HETLIOZ $904 48 payments
  3. CAPLYTA $888 55 payments
  4. ABILIFY MAINTENA $781 54 payments
  5. VRAYLAR $778 90 payments
  6. INGREZZA $703 52 payments
  7. REXULTI $570 36 payments
  8. ARISTADA Cns $565 30 payments
  9. ARISTADA Cns $565 30 payments
  10. SPRAVATO $519 32 payments
  11. Other $6,240 422 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 74 drugs

Part D claims

4,461

Median for Psychiatry: 574

Drug cost

$2,038,863

Median for Psychiatry: $27,624

Branded share of claims

30.6%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Austedo Deutetrabenazine Brand 92 $684,836
Invega Sustenna Paliperidone Palmitate Brand 129 $435,327
Abilify Maintena Aripiprazole Brand 48 $141,434
Ingrezza Valbenazine Tosylate Brand 16 $127,486
Vraylar Cariprazine Hcl Brand 82 $116,132
Fanapt Iloperidone Brand 35 $79,590
Trintellix Vortioxetine Hydrobromide Brand 95 $57,541
Rexulti Brexpiprazole Brand 31 $51,642
Caplyta Lumateperone Tosylate Brand 24 $39,463
Perseris Risperidone Brand 13 $38,919

The 10 drugs with the highest cost, of 74 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
CAPLYTA
  • ITI, Inc. $259
$259 24 —
INGREZZA
  • Neurocrine Biosciences, Inc. $150
$150 16 —
Auvelity
  • Axsome Therapeutics, Inc. $87
$87 — —
ARISTADA
  • Alkermes, Inc. $72
$72 — —
VRAYLAR
  • AbbVie, Inc. $63
$63 82 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

675 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record